Last updated on March 2020

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

Brief description of study

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). These patients are at high risk for progression of kidney disease, which can result in end-stage renal failure.

Clinical Study Identifier: NCT03841448

Find a site near you

Start Over

Clinical Trial Site

Hospitalet de Llobregat, Spain
  Connect »

Clinical Trial Site

Barcelona, Spain
  Connect »